Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Revenue (2016 - 2025)

Historic Revenue for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $207.6 million.

  • Corcept Therapeutics' Revenue rose 1374.56% to $207.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $741.2 million, marking a year-over-year increase of 1791.68%. This contributed to the annual value of $675.0 million for FY2024, which is 3994.09% up from last year.
  • Corcept Therapeutics' Revenue amounted to $207.6 million in Q3 2025, which was up 1374.56% from $194.4 million recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Revenue ranged from a high of $207.6 million in Q3 2025 and a low of $79.4 million during Q1 2021
  • Moreover, its 5-year median value for Revenue was $117.7 million (2023), whereas its average is $130.8 million.
  • Its Revenue has fluctuated over the past 5 years, first crashed by 1481.01% in 2021, then skyrocketed by 4768.97% in 2024.
  • Over the past 5 years, Corcept Therapeutics' Revenue (Quarter) stood at $98.8 million in 2021, then grew by 4.28% to $103.1 million in 2022, then skyrocketed by 31.39% to $135.4 million in 2023, then surged by 34.33% to $181.9 million in 2024, then rose by 14.16% to $207.6 million in 2025.
  • Its Revenue stands at $207.6 million for Q3 2025, versus $194.4 million for Q2 2025 and $157.2 million for Q1 2025.